APRIL Assay Portfolio Service
Background What We Can Offer Publication Why Choose Us FAQs Customer Review Related Services Contact Us
Unlocking Therapeutic Potential: A Comprehensive APRIL Assay Portfolio for Cancer Research
A proliferation-inducing ligand (APRIL, also known as TNFSF13) belongs to the tumor necrosis factor (TNF) ligand superfamily member 13. APRIL is expressed as a type-II transmembrane protein, but unlike most other TNF family members, it is rarely expressed at the cell membrane. Instead, it is cleaved in the Golgi apparatus by a furin convertase to release a soluble active form, which is subsequently secreted. APRIL has a 28-amino-acid cytoplasmic domain, a transmembrane domain, and a 201-residue extracellular domain consisting of a stalk and a TNF domain. Soluble, mature APRIL is an approximately 63-kDa non-covalent trimer. APRIL can also be exposed on the cell surface due to unique intergenic splicing between the TNF-related weak inducer of apoptosis (TWEAK) and APRIL locus, giving rise to a fusion protein called TWEPRIL. APRIL is closely related to the B cell-activating factor (BAFF), a member of the TNF ligand family. APRIL is expressed by a variety of immune cell subsets that also produce BAFF: monocytes, macrophages, dendritic cells (DCs), neutrophils, and T cells.
Fig.1 APRIL-mediated signaling pathways in multiple myeloma cells.1, 3
What We Can Offer?
APRIL has roles in cell proliferation, differentiation, motility, trafficking, apoptosis, and tissue architecture. Creative Biolabs' expertise and our commitment to high-quality standards can provide one-stop customized tumor marker assay services. Our APRIL assay portfolio services for research include, but are not limited to
-
Cell cycle and apoptosis analysis
-
Cell proliferation assay
-
Colony formation assay
-
Invasion and migration assays
-
Transfection and cell line construction
-
Immunoprecipitations and western blotting
-
Immunofluorescence and immunohistochemistry analysis
-
ELISA
-
Animal experiments
To best address your ever-changing needs, Creative Biolabs is continuously evolving. Please feel free to contact us.
Publication
Multiple myeloma (MM) remains an incurable hematological malignancy despite advances in treatment, with most patients eventually relapsing due to clonal heterogeneity and complex interactions with the bone marrow microenvironment. While B-cell maturation antigen (BCMA) has been the primary focus for immunotherapies such as CAR-T cells, antibody-drug conjugates, and bispecific antibodies, challenges like variable BCMA expression and antigen escape highlight the need for alternative targets.
This review explores transmembrane activator and CAML interactor (TACI), another TNF receptor superfamily member that shares ligands (BAFF and APRIL) with BCMA and plays overlapping roles in plasma cell survival and MM pathogenesis. We examine TACI's functions in normal B-cell biology, its contribution to MM progression, and its potential as a therapeutic target. Emerging strategies, including TACI-Fc fusion proteins, anti-APRIL antibodies, and dual-targeting CAR-T cells, demonstrate promising preclinical efficacy. By targeting TACI alongside BCMA, these approaches aim to overcome resistance mechanisms and improve outcomes for MM patients.
Fig.2 APRIL sources, receptors, and HSPG-mediated signaling.2, 3
Why Choose Us?
At Creative Biolabs, we leverage our extensive expertise in APRIL biology and advanced technological platforms to deliver precise, innovative research solutions. Our team possesses specialized knowledge of APRIL's unique receptor interactions, including its binding with TACI, BCMA, and heparan sulfate proteoglycans (HSPGs), as well as its critical role in tumor microenvironment dynamics. This enables us to generate more accurate and biologically relevant data than standard service providers.
Key Advantages:
-
Specialized expertise in APRIL-receptor interactions.
-
Advanced analysis of tumor microenvironment impacts.
-
Data-driven, biologically relevant insights.
-
Collaborative and customized research support.
-
Accelerated therapeutic development pathways.
FAQs
Q1: How do I know which APRIL assay is right for my project?
A1: Our comprehensive portfolio includes a wide range of assays. The best choice depends on your specific research goals, whether you are screening compounds, validating a target, or conducting biomarker studies.
Q2: What types of samples can be analyzed using your APRIL assays?
A2: Our services are highly versatile. We can analyze a broad range of samples, including established cancer cell lines, primary tumor tissues, blood plasma, and cerebrospinal fluid. We can also work with recombinant proteins and purified antibodies.
Q3: Can you help us with data interpretation and follow-up studies?
A3: Yes. Our service includes not only data generation but also a detailed final report with expert interpretation. We also provide consultation to discuss the results and recommend next steps, such as in vivo studies or further molecular analysis, to advance your project.
Customer Review
-
Improved Therapeutic Efficacy
Using Creative Biolabs' APRIL assay portfolio in our research has significantly improved the efficiency of our lead compound screening. Their ability to deliver customized, relevant data on APRIL's anti-apoptotic effects allowed us to rapidly identify the most promising therapeutic candidates for gastric cancer. - A.B., S****th
-
Enhanced Biomarker Discovery
The team's expertise in ELISA for sAPRIL detection was invaluable. Using Creative Biolabs' service in our study has significantly facilitated the discovery of APRIL as a diagnostic biomarker for CNS lymphoma, providing highly specific and reliable data for disease monitoring during therapy. - J.K., G****
Related Services
In Vivo Safety Pharmacology
Creative Biolabs is a leading provider of cancer immunotherapy discovery and development services. They offer independent or integrated services throughout the drug's life cycle, with a focus on safety pharmacology to detect and investigate potential adverse effects.
Learn More →
Reactive Metabolite Screening Service
Creative Biolabs provides reactive metabolite screening assays using state-of-the-art technology. Their assays, including glutathione, cysteine, and cyanide trapping assays, detect and quantify reactive metabolites to assess potential safety risks and provide insights into a drug's metabolic fate.
Learn More →
Contact Us
At Creative Biolabs, we are your strategic partner in immuno-oncology. We invite you to leverage our deep expertise and comprehensive APRIL assay portfolio service to accelerate your research and unlock the next generation of cancer therapies.
Just contact us for a free consultation to discuss your specific needs.
References
-
Nowacka, Kinga Henryka, and Ewa Jabłońska. "Role of the APRIL molecule in solid tumors." Cytokine & Growth Factor Reviews 61 (2021): 38-44. DOI: https://doi.org/10.1016/j.cytogfr.2021.08.001
-
Chang, Chuan-Hsin, et al. "EpCAM signaling in oral cancer stem cells: implications for metastasis, tumorigenicity, and therapeutic strategies." Current Issues in Molecular Biology 47.2 (2025): 123. DOI: https://doi.org/10.3390/cimb47020123
-
Distributed under Open Access license CC BY 4.0, without modification.
